HGH Fragment 176-191 vs Tesofensine
A side-by-side research comparison of HGH Fragment 176-191 and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | HGH Fragment 176-191 | Tesofensine |
|---|---|---|
| Full name | Human Growth Hormone Fragment 176-191 | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | Mimics lipolytic action of HGH by stimulating beta-3 adrenergic receptors on adipocytes, increasing cyclic AMP and hormone-sensitive lipase activity. Does not affect IGF-1. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | 1,817 Da | 329.4 Da |
| Half-life | 3-4 hours | 8-10 days |
| Bioavailability | High (SubQ) | High (oral ~93%) |
| Typical dose | 250-500 mcg | 0.25-0.5 mg |
| Frequency | 1-2x daily | Once daily |
| Route | Subcutaneous | Oral |
HGH Fragment 176-191 reported benefits
- Targeted fat loss
- No IGF-1 elevation
- No glucose impairment
- No bone/organ growth effects
- Improved body composition
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.